Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 1 Feb 2016

Cai Wenzhi, Liu Bin, Xu Yang, Chen Suning, Sun Aining, He Jun, Shen Hongjie, Wu Depei

Abstract excerpt

OBJECTIVE: To clarify the clinical, cytogenetical and molecular characteristics and prognosis of Ph(+) ALL patients with ABL kinase domain mutations (ABL-KDMs), and to evaluate the therapeutic value of allogeneic hematopoietic stem cell transplantation (allo-HSCT) combined with tyrosine kinase inhibitor (TKI) in these patients. METHODS: Retrospective analysis of clinical features, molecular genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Proto-Oncogene Proteins c-abl

Share to Pyrimidines

Share to Remission Induction

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 27014978
DOI: 10.3760/cma.j.issn.0253-2727.2016.02.004
PMCID: PMC7348204

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].PMID 27014978Read ↗

[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].Semantic proximity Read ↗

[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].Semantic proximity Read ↗

BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options.Semantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

Ph+ ALL: new approaches for upfront therapySemantic proximity Read ↗

Integrative Insights into Philadelphia-like B-Cell Acute Lymphoblastic Leukemia: A Genetic and Molecular LandscapeSemantic proximity Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

[Clinical Analysis of Gene Mutation in Adult Patients with B-ALL and Its Influence on Clinical Prognosis].Semantic proximity Read ↗

[Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].Semantic proximity Read ↗

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSemantic proximity Read ↗

Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.